Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
Christopher J.D. Wallis(University Health Network), Zachary Klaassen(Augusta University), Stephen J. Freedland(Cedars-Sinai Medical Center), Sumanta K. Pal(City of Hope), Sandip Pravin Patel(University of California San Diego), Omid Hamid(Cedars-Sinai Medical Center), Raj Satkunasivam(Methodist Hospital), Mohit Butaney(Brigham and Women's Hospital)
Cited by 302
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k